An event-driven, phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficiency, safety, immunogenicity, & lot-to-lot consistency of Bbv152, a whole-varion inactivated Sars-Cov-2 vaccine in adults more than 18 to years of age
Implementing Organization
ICMR-National Institute of Research In Tribal Health Madhya Pradesh
Principal Investigator
Mr. M. Shameem Professor ICMR-National Institute of Research In Tribal Health Madhya Pradesh
ICMR-National Institute of Research In Tribal Health Madhya Pradesh
Accessibility Controls